Literature DB >> 20186552

Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications.

Takayuki Fujita1, Norikazu Ogihara, Yumi Kamura, Atsushi Satomura, Yoshinobu Fuke, Chie Shimizu, Yuki Wada, Koichi Matsumoto.   

Abstract

Diabetic complication is comprised of a wide variety of pathophysiological factors involving proinflammatory cytokines, adipokines, and oxidative stress, among others. Each of these complications differs in their incidence and the stage of their occurrence. We examined cytokines and stress markers in 48 patients with type 2 diabetes mellitus and compared the difference of their contribution to pathogenesis between nephropathy and other diabetic complications. Hemoglobin A1c correlated with the level of low-density lipoprotein-cholesterol, and significantly elevated in the severe macroangiopathy group. Cystatin C increased in the severe microangiopathy groups but did not increase in the macroangiopathy group. The levels of interleukin 18 (IL-18), high-sensitive CRP (H-CRP), liver-type fatty acid binding protein, and 8-hydroxy-2-deoxyguanosine increased in the severe microangiopathy group. These data suggest the participation of proinflammatory signaling and oxidative stress in the progression of microangiopathy. In particular, IL-18 and H-CRP were significantly elevated only in the severe nephropathy group but did not significantly elevate in other complications. These data suggest another effect of IL-18 on glomerulus in addition to its proinflammatory effect. In conclusion, we propose that IL18 has a specific role that contributes more closely to the progression of diabetic nephropathy than other diabetic complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186552     DOI: 10.1007/s00592-010-0178-4

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  20 in total

Review 1.  Biotransformation effect of Bombyx Mori L. may play an important role in treating diabetic nephropathy.

Authors:  Lei Zhang; Yin Li; Xin-Feng Guo; Xu-Sheng Liu
Journal:  Chin J Integr Med       Date:  2015-12-19       Impact factor: 1.978

Review 2.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Javier García-Pérez
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

Review 3.  The role of interleukin-18 in the metabolic syndrome.

Authors:  Marius Trøseid; Ingebjørg Seljeflot; Harald Arnesen
Journal:  Cardiovasc Diabetol       Date:  2010-03-23       Impact factor: 9.951

Review 4.  Diabetic nephropathy--emerging epigenetic mechanisms.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

5.  Cross-sectional correlates of increased IL-18 but reduced fetuin-A and oxytocin with adiposity and blood indices in metabolic syndrome patients with and without prediabetes.

Authors:  Violet Kasabri; Esraa Shawakri; Amal Akour; Randa Naffa; Nahla Khawaja; Ibrahim Al-Sarraf; Jameel Bzour
Journal:  Ther Adv Endocrinol Metab       Date:  2018-08-18       Impact factor: 3.565

6.  hs-CRP Is Associated With Incident Diabetic Nephropathy: Findings From the Jackson Heart Study.

Authors:  Satyesh K Sinha; Susanne B Nicholas; Jung Hye Sung; Adolfo Correa; Tripathi B Rajavashisth; Keith C Norris; Jae Eun Lee
Journal:  Diabetes Care       Date:  2019-09-11       Impact factor: 17.152

7.  NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients.

Authors:  Jasna Klen; Katja Goričar; Andrej Janež; Vita Dolžan
Journal:  J Diabetes Res       Date:  2015-07-27       Impact factor: 4.011

8.  Is the inflammasome a potential therapeutic target in renal disease?

Authors:  Clare M Turner; Nishkantha Arulkumaran; Mervyn Singer; Robert J Unwin; Frederick W K Tam
Journal:  BMC Nephrol       Date:  2014-01-23       Impact factor: 2.388

9.  Interleukin-18 can predict pre-clinical atherosclerosis and poor glycemic control in type 2 diabetes mellitus.

Authors:  Zhian M Ibrahim Dezayee
Journal:  Int J Appl Basic Med Res       Date:  2011-07

10.  A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus.

Authors:  Elizabeth A McKie; Juliet L Reid; Prafull C Mistry; Stephen L DeWall; Lee Abberley; Philip D Ambery; Blas Gil-Extremera
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.